Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2018 development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2018 pipeline products by developmental stage, product type, molecule type, and administration route.

Scope

  • The report provides a snapshot of the pipeline development for the Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2018
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2018
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2018
  • The report also covers the dormant and discontinued pipeline projects related to the Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2018

Companies Featured

  • AB Science SA
  • Seattle Genetics
  • Solasia Pharma
  • Celgene
  • CerRx, Inc
  • Incyte Corporation
  • Kura Oncology
  • Eisai Co Ltd
  • Merck & Co

Key Topics Covered

1. Report Introduction

2. Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2018 Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2018

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/h6d4zx/peripheral_tcell?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900